Community Acquired Pneumonia – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

    1.1. Report Overview

2. Community Acquired Pneumonia - Overview

3. Executive Summary

4. Community Acquired Pneumonia: Pipeline Assessment

    4.1. By Stage of Development

    4.2. By Route of Administration

    4.3. By Drug Class

    4.4. By Molecule Type

    4.5. By Therapy Area / Indication

    4.6. By Drug Target

    4.7. By Sponsor

5. Community Acquired Pneumonia: Company & Drug Profiles

    5.1. Clinical Stage

        5.1.1. CAL02 – Combioxin SA

            5.1.1.1. Company Overview

            5.1.1.2. Product Description

            5.1.1.3. R&D Status & Development Activities

            5.1.1.4. Mechanism of Action

            5.1.1.5. Molecule Type

            5.1.1.6. Stage of Development

            5.1.1.7. Indications

            5.1.1.8. Route of Administration

            5.1.1.9. Funding

        5.1.2. Cx611 – Tigenix S.A.U.

            5.1.2.1. Company Overview

            5.1.2.2. Product Description

            5.1.2.3. R&D Status & Development Activities

            5.1.2.4. Mechanism of Action

            5.1.2.5. Molecule Type

            5.1.2.6. Stage of Development

            5.1.2.7. Indications

            5.1.2.8. Route of Administration

            5.1.2.9. Funding

        5.1.3. Nafithromycin – Wockhardt

            5.1.3.1. Company Overview

            5.1.3.2. Product Description

            5.1.3.3. R&D Status & Development Activities

            5.1.3.4. Mechanism of Action

            5.1.3.5. Molecule Type

            5.1.3.6. Stage of Development

            5.1.3.7. Indications

            5.1.3.8. Route of Administration

            5.1.3.9. Funding

        5.1.4. Others

    5.2. Preclinical

        5.2.1. Company Overview

        5.2.2. Product Description

        5.2.3. R&D Status & Development Activities

        5.2.4. Mechanism of Action

        5.2.5. Molecule Type

        5.2.6. Indications

        5.2.7. Route of Administration

        5.2.8. Funding

6. Community Acquired Pneumonia: An Overview on Dormant & Discontinued Pipeline Candidates

    6.1. Overview

    6.2. Product Description

    6.3. Reason for Discontinuation

7. Community Acquired Pneumonia: Additional Key Insights

    7.1. Epidemiology Overview: Community Acquired Pneumonia

    7.2. Current Market Scenario: Community Acquired Pneumonia Therapeutics

8. Community Acquired Pneumonia: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.